Search results
Showing 5251 to 5265 of 7685 results
Recommendation ID PH38/3 Question Identification and monitoring:- What are the most effective and cost-effective methods of increasing
How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period?
Recommendation ID CG192/2 Question How safe are drugs used to treat bipolar disorder in pregnancy and the postnatal period? Any explanatory
Recommendation ID PH38/1 Question Identification and monitoring:- Which combination of risk-assessment tools and blood tests (HbA1c or
Recommendation ID NG207/04 Question Intrauterine fetal death after previous caesarean birth: How should labour be induced in women with
Recommendation ID NG86/3 Question Identifying barriers and enablers to using the views and experiences of people who use services to improve
Recommendation ID NG212/07 Question Identifying employees at risk of poor mental wellbeing: What tools (for example, wellbeing surveys)
Recommendation ID NG25/2 Question Identifying infection in women with preterm prelabour rupture of membranes (P-PROM):- What is the diagnostic
Recommendation ID NG32/2 Question Identifying older people at high risk:- In the UK, what are the most effective ways to identify older
Recommendation ID NG38/3 Question Image guidance in the reduction of displaced distal radius fractures:- For patients with displaced fractures
Recommendation ID CG122/3 Question Imaging in the diagnostic pathway for women with ovarian cancer:- Large multicentre case–control studies
Recommendation ID NG35/2 Question Imaging investigations for newly diagnosed myeloma:- What is the comparative effectiveness of whole-body
Recommendation ID NG38/1 Question Imaging of ankle fractures:- Is CT scanning in addition to initial plain film X-ray clinically effective
What are the effective forms of immobilisation for people with MSCC?
Recommendation ID NG234/2 Question What are the effective forms of immobilisation for people with MSCC? Any explanatory notes(if
Recommendation ID NG122/1 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non-small-cell
Recommendation ID NG122/01 Question What is the effectiveness and cost effectiveness of immunotherapy in people with stage IIIA-N2 non‑small‑cell